Pregnant in 2026: Matching ACOG vs CDC timing for RSV and COVID-19

If you’re pregnant (or planning for pregnancy) in 2026, you may have seen two sets of “official” guidance that don’t line up perfectly—ACOG’s pregnancy immunization schedule and CDC’s vaccine tables. Don’t panic: the difference is often about how the guidance is organized, not about the vaccines themselves.

The practical takeaway is timing. For RSV, the timing of maternal vaccination matters because antibodies need time to transfer to the baby. If that maternal timing doesn’t fit the recommended window, CDC’s guidance shifts to protecting the infant with the RSV monoclonal antibody (nirsevimab). For COVID-19, ACOG emphasizes vaccination during pregnancy as soon as possible, while CDC may not list COVID-19 on the general “vaccinating pregnant women” table—because CDC provides separate, dedicated COVID-19 pregnancy recommendations.

ACOG in 2026: COVID-19 any trimester; RSV Abrysvo in a defined window

In ACOG’s 2026 Maternal Immunization Schedule, the two decision-relevant items for this explainer are:

COVID-19: ACOG lists COVID-19 vaccination as something that can occur in any trimester, with emphasis on getting vaccinated as soon as possible.
Seasonal RSV (Abrysvo): ACOG lists Abrysvo (the RSV vaccine) as a one-time dose in the first eligible pregnancy, given during 32 weeks 0 days through 36 weeks 6 days. ACOG also includes an additional seasonal planning note for most of the continental U.S.

ACOG also includes an important “planning” point for future pregnancies: if a person already received Abrysvo in a prior pregnancy, ACOG indicates repeat maternal RSV vaccination is not indicated, and infant monoclonal antibody planning is used instead.

Why CDC can look different at first glance: table view vs dedicated pages

CDC’s pregnancy vaccine “table view” (Guidelines for Vaccinating Pregnant Women) may show a row for COVID-19 that reads “No guidance/not applicable.” The intent is not to say pregnancy COVID-19 vaccination is irrelevant—it reflects that the table is not where CDC places the detailed COVID-19 pregnancy recommendations.

CDC provides those recommendations on a separate, dedicated COVID-19 pregnancy guidance page, which explains current vaccine recommendations for pregnant and breastfeeding people.

CDC’s RSV pregnancy timing rules (and what happens if you’re outside the window)

CDC’s RSV guidance is built around two linked timing ideas: (1) maternal vaccination timing relative to gestational age, and (2) RSV season planning so protection is available at birth.

Gestational age window: CDC recommends maternal Abrysvo for women who are 32 0/7 through 36 6/7 weeks gestation.
Season window (most of the continental U.S.): CDC frames the season window so vaccination occurs before the period when RSV is most likely to circulate, to help protect the infant at birth.
If you’re beyond the gestational-age cutoff: CDC advises that pregnant people more than 36 weeks 6 days pregnant should not receive maternal RSV vaccine, because there may not be enough time for antibodies to develop and cross the placenta. In those situations, CDC’s approach shifts to infant protection with nirsevimab around the start of the RSV season.
If maternal vaccination timing falls outside the recommended seasonal timeframe: CDC generally directs clinicians to use nirsevimab for infant protection rather than relying on maternal vaccination outside the recommended period.

The “most families” RSV rule: maternal Abrysvo OR infant nirsevimab (usually not both)

Both ACOG and CDC describe the same core operational approach: for most infants, protection comes from one product choice based on eligibility and timing (not a blanket “both for everyone” rule).

CDC’s RSV guidance emphasizes that, for most infants, preventing severe RSV disease involves either maternal RSV vaccination or infant immunization with the RSV monoclonal antibody (nirsevimab)—with most infants not needing both.
ACOG mirrors this in its pregnancy scheduling logic: Abrysvo is planned for the first eligible pregnancy, and infant monoclonal antibody planning is used when maternal vaccination isn’t repeated (including after prior maternal Abrysvo use).

What changes from family to family is the product choice: where you are in pregnancy relative to the gestational-age window, whether maternal vaccination occurred in the recommended timeframe, and whether maternal Abrysvo was used in a prior pregnancy. CDC’s timing framework is the tool for mapping those situations to the right plan.

New real-world evidence: why “timing matters” for infant protection

A new real-world study published in JAMA Network Open (published online June 5, 2026) evaluated maternal RSVpreF vaccination and RSV-associated hospitalizations among infants.

This study was a retrospective case-control analysis (test-negative design) within a single health system in western Pennsylvania during the first two RSV seasons after RSVpreF implementation (including 2023–2024 and 2024–2025).

The study’s findings supported a “timing matters” message: effectiveness estimates for protection against RSV-associated hospitalization were lower when the time between vaccination and delivery was shorter (and in some subgroup analyses). That pattern aligns with why guidance focuses on vaccinating within the recommended gestational window.

Important limitation: because this was an interim analysis within one health system with relatively limited case numbers and wide uncertainty in places, it should be seen as early real-world context—not as a replacement for the CDC/ACOG timing framework.

Safety and eligibility: what FDA labeling covers for Abrysvo

FDA’s prescribing information for Abrysvo describes it as indicated for active immunization of pregnant individuals at 32 through 36 weeks gestational age to help prevent RSV lower respiratory tract disease in infants from birth through 6 months of age.

The labeling also includes safety information that readers should review with their clinician, including contraindications related to a history of severe allergic reaction to any component. FDA also notes there is a pregnancy exposure registry for people exposed to Abrysvo during pregnancy.

What readers can do now (without guessing)

Use ACOG as your “what to coordinate” checklist: bring ACOG’s schedule for COVID-19 in pregnancy (any trimester, as soon as possible) and the RSV Abrysvo gestational-age window for the first eligible pregnancy.
Use CDC pages to confirm the timing logic: CDC’s dedicated RSV pregnancy guidance explains what to do when maternal RSV vaccination falls outside the recommended window, including when infant nirsevimab is used.
Ask your OB/midwife which product applies to your situation: this matters most if you’re close to the gestational-age cutoff, planning a due date around RSV season, or trying to determine what plan applies given whether Abrysvo was used earlier in pregnancy or in a prior pregnancy.

Bottom line: the “ACOG vs CDC” mismatch usually comes from format (CDC’s general table vs CDC’s dedicated COVID-19 pregnancy guidance). For RSV, the two organizations align more than they appear to: both rely on CDC’s timing framework to match families to the right protection plan—maternal Abrysvo versus infant nirsevimab—based on gestational-age and seasonal eligibility.

Sources

Editorial note: Weence articles are researched from cited public-health, medical, regulatory, journal, and reputable news sources and may be drafted with AI assistance. They are checked for source support, clarity, and safety guardrails before publication.

This article is for general informational purposes only and is not medical advice. Research findings can be early or incomplete, and health guidance can change. Always talk with a qualified healthcare professional about personal symptoms, diagnosis, medications, vaccines, screenings, or treatment decisions. If you think you may have a medical emergency, call emergency services right away.